| European Rare Blood Disorders Platform (ENROL) (NCT06250595) | Hospital Universitari Vall d'Hebron Research Institute | 2022-07-01 |
| Dual-Energy Computed Tomography for Improving Imaging Assessment of Multiple Myeloma (NCT05353907) | Guy's and St Thomas' NHS Foundation Trust | 2022-06-01 |
| Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic Malignancy (NCT05154474) | Weprom | 2022-06-01 |
| A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma (NCT05055063) | M.D. Anderson Cancer Center | 2022-05-18 |
| Repeated HBO Therapy in Myeloma Patients Undergoing High-Dose Therapy and Auto-HCT (NCT04862676) | University of Rochester | 2022-04-22 |
| Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients (NCT04843579) | Weill Medical College of Cornell University | 2021-12-29 |
| A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. (NCT05228470) | Pfizer | 2021-12-21 |
| Understanding Patterns of Fatigue in Health and Disease (NCT05622669) | University of Aberdeen | 2021-12-07 |
| SABRE: A Single-arm Prospective Study Measuring Safety and Tolerability of SARS-CoV-2 Neutralising Antibodies in High-risk Populations (NCT05393999) | Imperial College Healthcare NHS Trust | 2021-11-29 |
| Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy (NCT05065866) | H. Lee Moffitt Cancer Center and Research Institute | 2021-11-18 |
| Continuous Temperature Monitoring for tHe Early Recognition of Febrile Neutropenia in Haematological MALignancies (NCT05203809) | Malaghan Institute of Medical Research | 2021-11-18 |
| FT576 in Subjects With Multiple Myeloma (NCT05182073) | Fate Therapeutics | 2021-11-10 |
| Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies (NCT05528887) | The Affiliated People's Hospital of Ningbo University | 2021-09-16 |
| Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). (NCT04751877) | Poitiers University Hospital | 2021-07-17 |
| Removing Transfusion Dependence as a Barrier to Hospice Enrollment (NCT05063591) | Adam Olszewski | 2021-07-09 |
| Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma (NCT04680468) | University of Pennsylvania | 2021-06-02 |
| Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults (NCT04952766) | Centre Hospitalier Régional d'Orléans | 2021-03-26 |
| Feasibility of an Adapted Physical Activity Program for Patients Treated With an Autograft (APA²) (NCT04320420) | Weprom | 2020-11-20 |
| FT538 in Subjects With Advanced Hematologic Malignancies (NCT04614636) | Fate Therapeutics | 2020-10-17 |
| A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment (NCT04268199) | AHS Cancer Control Alberta | 2020-05-29 |
| Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation (NCT03836690) | University College, London | 2019-10-21 |
| Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma (NCT03695744) | Singapore General Hospital | 2019-10-02 |
| PROactive Evaluation of Function to Avoid CardioToxicity (NCT03862131) | Washington University School of Medicine | 2019-03-13 |
| Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma (NCT03500445) | University of Chicago | 2019-02-13 |
| Vascular Functions in Myeloma Patients During Anti-tumor Therapy (NCT03776331) | University Hospital, Essen | 2018-12-28 |
| MRI in Multiple Myeloma: Analysis of the Axial Skeleton Versus Whole Body. What is the Required Analysis? (NCT03618212) | Centre Hospitalier Universitaire de Nīmes | 2018-12-21 |
| Place of the Hevylite Test in the Evaluation of MRD in Myeloma (NCT03702088) | University Hospital, Montpellier | 2018-10-01 |
| A Study of the Bortezomib, Lenalidomide, and Dexamethasone Regimen for the Treatment of Newly Diagnosed Multiple Myeloma Patients (NCT07206810) | The First Affiliated Hospital of Soochow University | 2018-08-01 |
| Machine Learning in Myeloma Response (NCT03574454) | Royal Marsden NHS Foundation Trust | 2018-07-04 |
| Effects of Hyperbaric Oxygen (HBO) on Blood Count Recovery After Autologous Hematopoietic Stem Cell (HSPC) Transplant for Multiple Myeloma (NCT03398200) | Omar Aljitawi | 2018-05-10 |
| The Development and Pilot Testing of a New MR Imaging Protocol to Quantify Myeloma Disease Burden and Bone Loss (NCT03951220) | Oxford University Hospitals NHS Trust | 2018-03-29 |
| Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment. (NCT03314636) | Oslo University Hospital | 2018-03-16 |
| Nivolumab Combined With Daratumumab With or Without Low-dose Cyclophosphamide (NCT03184194) | Amsterdam UMC, location VUmc | 2018-02-21 |
| Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors (NCT03302403) | Kang YU | 2017-12-29 |
| Effects of Aerobic Training and Inspiratory Muscle Training in Patients During Hematopoietic Stem Cell Transplantation (NCT03373526) | Daniel Godoy Martinez | 2017-11-11 |
| WB-EMS and Nutrition in Patients With Hematological Malignancies (NCT03556748) | University of Erlangen-Nürnberg Medical School | 2017-11-01 |
| Liquid Biopsy Evaluation and Repository Development at Princess Margaret (NCT03702309) | University Health Network, Toronto | 2017-08-03 |
| Low Dose Plerixafor Plus G-CSF in Mobilizing Stem Cells for Autologous Peripheral Blood Transplantation (NCT03244930) | Hospital Universitario Dr. Jose E. Gonzalez | 2017-05-10 |
| Bergamo Lymphoid Cancer Registry (NCT03131531) | A.O. Ospedale Papa Giovanni XXIII | 2017-03-23 |
| Mobile Health Device Study for Myeloma Patients (NCT03006315) | Memorial Sloan Kettering Cancer Center | 2016-12-01 |
| Feasibility of Pre Transplant Exercise (Pre-habilitation) for Multiple Myeloma Patients Awaiting Autologous Stem Cell Transplantation (NCT03135925) | Sheffield Teaching Hospitals NHS Foundation Trust | 2016-09-01 |
| Changing Over Time of Ascorbic Acid After Chemotherapy (NCT02931942) | Maastricht University Medical Center | 2016-09-01 |
| Positron Emission Tomography (PET) Imaging Studies With NIS Reporter (NCT02907073) | Mayo Clinic | 2016-09-01 |
| Ascending Dose and Exploratory Expansion Study of DS-3032b, an Oral MDM2 Inhibitor, in Subjects With Relapsed and/or Refractory Multiple Myeloma (NCT02579824) | M.D. Anderson Cancer Center | 2016-08-30 |
| PET Imaging of Subjects Using 124I-PU-AD (NCT03371420) | Samus Therapeutics, Inc. | 2016-04-01 |
| The Value of Systematic Biopsies During Vertebroplasty for the Treatment of Osteoporotic Vertebral Fractures (NCT06153576) | Centre Hospitalier Universitaire de Nice | 2016-01-01 |
| Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis (NCT02593123) | Virginia Commonwealth University | 2015-11-04 |
| Feasibility and Safety of Functional Performance Testing in Patients Undergoing Hematopoietic Cell Transplantation (NCT02598752) | Memorial Sloan Kettering Cancer Center | 2015-11-01 |
| Ixazomib with Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients with Multiple Myeloma (NCT02542657) | Joseph Tuscano | 2015-10-01 |
| African American Cancer Clinical Trial Decisions: Testing Tailored Messages (NCT02356549) | Virginia Commonwealth University | 2015-05-01 |
| Imageguided Theranostics in Multiple Myeloma (NCT02403102) | Institute of Cancer Research, United Kingdom | 2015-03-26 |
| Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma (NCT02188537) | Swiss Cancer Institute | 2014-12-02 |
| Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma (NCT02114502) | M.D. Anderson Cancer Center | 2014-09-01 |
| Evaluation of the Use of Apixaban in Prevnetion of Thromboembolic Disease in Patients With Myeloma Trated With iMiDs (NCT02066454) | University Hospital, Grenoble | 2014-06-05 |
| Cryotherapy Against Oral Mucositis After High-dose Melphalan (NCT03704597) | Sahlgrenska University Hospital | 2014-03-01 |
| Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis (NCT01807286) | M.D. Anderson Cancer Center | 2014-01-01 |
| Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT) (NCT01927718) | M.D. Anderson Cancer Center | 2014-01-01 |
| Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene (NCT01875237) | M.D. Anderson Cancer Center | 2013-12-27 |
| Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma (NCT01985477) | M.D. Anderson Cancer Center | 2013-12-01 |
| Combination of G-CSF, Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Multiple Myeloma (NCT02027220) | Second Affiliated Hospital of Soochow University | 2013-12-01 |
| IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT (NCT01885897) | Masonic Cancer Center, University of Minnesota | 2013-11-11 |
| Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell Transplant (NCT01904175) | Duke University | 2013-08-01 |
| PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative (NCT01916135) | Memorial Sloan Kettering Cancer Center | 2013-07-01 |
| Intervention for Symptom Burden During Maintenance Therapy for Multiple Myeloma (NCT01793051) | M.D. Anderson Cancer Center | 2013-03-22 |
| Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM) (NCT01531998) | M.D. Anderson Cancer Center | 2012-05-01 |
| Clinical Ex Vivo Expansion of Human Umbilical Cord Blood Stem and Progenitor Cells (NCT01624701) | Singapore General Hospital | 2012-03-01 |
| A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives (NCT01532635) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2012-03-01 |
| Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies (NCT00943319) | University of Chicago | 2012-03-01 |
| Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT) (NCT01518153) | M.D. Anderson Cancer Center | 2012-02-01 |
| Testing a Spanish Version of a Patient Toxicity Questionnaire (NCT01517152) | National Cancer Institute (NCI) | 2012-01-04 |
| Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide (NCT01432600) | H. Lee Moffitt Cancer Center and Research Institute | 2011-11-01 |
| Donor Lymphocyte Infusion After Stem Cell Transplant in Treating Patients With Haematological Cancers (NCT01240525) | University College, London | 2011-11-01 |
| A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma (NCT01413178) | M.D. Anderson Cancer Center | 2011-09-30 |
| Stem Cell Transplantation for Patients With Multiple Myeloma (NCT01526096) | University of Chicago | 2011-07-12 |
| Cyclophosphamide and Pulse Dexamethasone With Rapamycin or Hydroxychloroquine (NCT01396200) | Abramson Cancer Center at Penn Medicine | 2011-06-01 |
| Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma (NCT01245673) | University of Pennsylvania | 2011-05-10 |
| Phase II Study of Simvastatin for Relapsed/Refractory Myeloma (NCT01332617) | University of Louisville | 2011-04-01 |
| Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps (NCT01350258) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2011-04-01 |
| A Trial of TBL12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma (NCT01302366) | NYU Langone Health | 2011-02-01 |
| Prevention of Treatment Induced Neuropathy in Multiple Myeloma (NCT01283997) | M.D. Anderson Cancer Center | 2011-01-25 |
| PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study (NCT01269593) | Memorial Sloan Kettering Cancer Center | 2010-12-01 |
| High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma (NCT01237951) | M.D. Anderson Cancer Center | 2010-11-08 |
| A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma (NCT01248455) | National Cancer Institute (NCI) | 2010-11-01 |
| Prognostic Study of Markers of Angiogenesis and Coagulability in Patients With Monoclonal Gammopathy (NCT01543100) | Rennes University Hospital | 2010-11-01 |
| Trial of Carfilzomib Plus Melphalan and Prednisone in Elderly Untreated Patients With Multiple Myeloma (CARMYSAP) (NCT01279694) | Nantes University Hospital | 2010-10-01 |
| Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant (NCT01174082) | M.D. Anderson Cancer Center | 2010-07-20 |
| Evaluation of the Drug Plerixafor in Combination With Chemotherapy and G-CSF for Stem Cell Collection (NCT01095757) | Emory University | 2010-03-01 |
| Lenalidomide and High-Dose Melphalan (NCT01079936) | M.D. Anderson Cancer Center | 2010-03-01 |
| Chemotherapy-Induced Peripheral Neuropathy Survey (NCT01016028) | M.D. Anderson Cancer Center | 2009-11-01 |
| Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients (NCT00983346) | University of Utah | 2009-10-01 |
| Pharmacogenomic Study in Myeloma Patients Treated With Melphalan-prednisone-thalidomide or Lenalidomide-dexamethasone (NCT00907452) | Intergroupe Francophone du Myelome | 2009-07-29 |
| Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL (NCT00881920) | Baylor College of Medicine | 2009-07-01 |
| Combination of Lenalidomide and Autologous Mature Dendritic Cells Pulsed With KRN7000 in Myeloma (NCT00698776) | Yale University | 2009-04-01 |
| Acupuncture for Chemo-Induced Peripheral Neuropathy (NCT00891618) | M.D. Anderson Cancer Center | 2009-04-01 |
| Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy (NCT00871013) | University of Arkansas | 2009-03-01 |
| Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide (NCT00800839) | M.D. Anderson Cancer Center | 2008-09-01 |
| Stem Cell Mobilization With Pegfilgrastim in Lymphoma and Myeloma (NCT00794261) | Centre Leon Berard | 2008-09-01 |
| Prospective Observational Study on Plerixafor After Chemotherapy (NCT01700608) | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 2008-09-01 |
| Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma (NCT01042704) | Robert Redner, MD | 2008-02-01 |
| Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant (NCT00597714) | David Rizzieri, MD | 2008-02-01 |